Metastatic Male Breast Cancer With Increased Uptake on 18F-Fluciclovine PET/CT Scan

Abstract Prostate imaging with 18F-labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC, 18F-fluciclovine) PET/CT scan (Axumin) was recently approved by the US Food and Drug Administration for men with suspected prostate cancer recurrence based on elevated blood prostate-specific antigen levels following prior treatment. We present a rare case of a 77-year-old man with suspected recurrent prostate cancer with an incidental finding of advanced-stage breast cancer showing different degrees of 18F-fluciclovine uptake. Received for publication June 10, 2017; revision accepted October 9, 2017. Conflicts of interest and sources of funding: none declared. Correspondence to: Harkanwar S. Gill, MD, Division of Nuclear Medicine, Department of Diagnostic Radiology, Loyola University Medical Centre, 2160 S 1st Ave, Maywood, IL 60153. E-mail: hksgill9@gmail.com. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2BbqTZL
via IFTTT